Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGU

Predictors of distant metastases at 68Ga-PSMA-11 PET/CT in early-recurrent hormone-sensitive prostate cancer (HSPC) patients

Guido Rovera, Serena Grimaldi, Sara Dall'Armellina, Roberto Passera, Marco Oderda, Giuseppe Iorio, Alessia Guarneri, Paolo Gontero, Umberto Ricardi and Desiree Deandreis
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 3075;
Guido Rovera
1Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serena Grimaldi
1Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Dall'Armellina
1Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Passera
2Division of Nuclear Medicine, Department of Medical Sciences, University of Turin, A.O.U. Città della Salute e della Scienza, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Oderda
3Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Iorio
4Radiation Oncology, Department of Oncology, AOU Città della Salute e della Scienza di Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessia Guarneri
4Radiation Oncology, Department of Oncology, AOU Città della Salute e della Scienza di Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Gontero
3Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Umberto Ricardi
4Radiation Oncology, Department of Oncology, AOU Città della Salute e della Scienza di Torino, Turin, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Desiree Deandreis
5Nuclear Medicine Unit, Department of Medical Sciences, University of Turin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

3075

Introduction: Prostate-specific-membrane-antigen/positron-emission-tomography (PSMA-PET) has shown better performance compared to conventional imaging in detecting disease relapse in prostate cancer (Pca) patients with early biochemical recurrence, allowing for more accurate restaging and leading to management changes based on personalized image-guided treatments. A high rate of management changes driven by PSMA-PET is observed in patients with evidence of distant metastatic involvement. These patients should thus be promptly identified and recommended for a PSMA-PET scan.Therefore, the aim of this study was to identify predictors of distant metastases (nodal M1a, skeletal M1b or visceral M1c) at PSMA-PET in early-recurrent hormone-sensitive Pca (HSPC) patients.

Methods: A retrospective analysis was conducted on four hundred forty-three (443) 68Ga-PSMA-11 PET/CT scans performed between November 2016 and December 2021 at our institution. According to guidelines, Pca patients undergoing PSMA-PET were hormone-sensitive, hormone-therapy free, previously treated with radical intent (radiotherapy or radical-prostatectomy ± salvage-RT) and had proven biochemical recurrence or persistence (BCR/BCP).For each patient, the collected data included information about disease staging, histopathologic grading, primary and salvage treatments, and kinetics of prostate-specific antigen (PSA). The association between clinical parameters and distant metastases (M1a/b/c) at imaging was analyzed using the Mann-Whitney/Fisher’s exact tests and a complete series of uni-/multi-variate binary logistic regression models.

Results: Patients’ median PSA at the time of PSMA-PET scan was 0.60 [IQR:0.38–1.04] ng/mL. PSMA-PET successfully localized disease recurrence in 42.0% (186/443) of cases. Locoregional relapse (prostate bed or pelvic LNs) was detected in 21.0% (93/443) of cases. Metastatic involvement (M1a/b/c) was present in 17.6% (78/443) of cases: 7.7% (34/443) nodal (M1a), 9.9% (44/443) skeletal (M1b) and 2.5% (11/443) visceral (M1c). 80.8% (63/78) of metastatic cases were oligometastatic (≤ 3 PSMA-positive lesions).A significant association with distant metastases (M1a/b/c) at PSMA-PET was demonstrated for T-stage (≥ 3a, p=0.001), ISUP-grade 5 (p=0.001), clinical-setting (previous salvage-RT or BCP vs first-time BCR, p<0.001), PSA doubling-time (PSAdt, p<0.001) and PSA value at PET-scan (p<0.001).At univariate binary logistic regression analysis, T-stage (≥ 3a), ISUP-grade 5, clinical-setting (previous salvage-RT or BCP) and PSAdt were proven to be significant predictors of metastatic involvement (M1a/b/c). These results were confirmed also by the multivariate model (accuracy: 67.4% - Nagelkerke R2: 17%): T-stage (OR:1.92; 95CI%:1.04-3.58; p=0.039), ISUP-grade (OR:2.14; 95CI%:1.09-4.23; p=0.028), clinical setting (OR:2.82; 95CI%:1.58-5.04; p<0.001), and PSAdt (OR:0.95; 95CI%:0.92-0.99; p=0.012).

Conclusions: T-stage (≥3a), ISUP grade (5), clinical setting (previous salvage-RT or BCP), and PSAdt were found to be significant predictors of distant metastatic involvement (M1a/b/c), with a 5% risk increment for each single-unit decrement of PSAdt. These parameters could help to stratify early-BCR/BCP HSPC-patients according to the likelihood of distant metastases, in order to refine the indication for PSMA-PET.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of distant metastases at 68Ga-PSMA-11 PET/CT in early-recurrent hormone-sensitive prostate cancer (HSPC) patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Predictors of distant metastases at 68Ga-PSMA-11 PET/CT in early-recurrent hormone-sensitive prostate cancer (HSPC) patients
Guido Rovera, Serena Grimaldi, Sara Dall'Armellina, Roberto Passera, Marco Oderda, Giuseppe Iorio, Alessia Guarneri, Paolo Gontero, Umberto Ricardi, Desiree Deandreis
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3075;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Predictors of distant metastases at 68Ga-PSMA-11 PET/CT in early-recurrent hormone-sensitive prostate cancer (HSPC) patients
Guido Rovera, Serena Grimaldi, Sara Dall'Armellina, Roberto Passera, Marco Oderda, Giuseppe Iorio, Alessia Guarneri, Paolo Gontero, Umberto Ricardi, Desiree Deandreis
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3075;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Semi-automatic Segmentation of Metastatic Tumor Load for 177Lu-PSMA Therapy
  • [68Ga]-PSMA-11 can clarify equivocal lesions on conventional imaging and change management decisions among men with previously treated prostate cancer
  • Can primary PET/CT staging using [68Ga]Ga-RM2 and [18F]Choline predict recurrence in prostate cancer?
Show more GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire